Dyne Therapeutics (NASDAQ: DYN) was hardly having a bad case of the Mondays. Shares of the clinical-stage biotech were racing more than 9% higher in mid-session action, as the company delivered rather ...

Dyne Therapeutics (NASDAQ: DYN) had a Monday neither it nor its investors will ever forget. This wasn't of its own making, however, as a premium-priced buyout of a peer was attracting serious interest ...

Oppenheimer upgraded Dyne Therapeutics (DYN) on Wednesday, citing a positive read-through from data that Novartis’ (NVS) buyout target Avidity Biosciences (RNA) is set to release this year from a late ...

The biotech announced a secondary stock issue. It aims to sell $300 million worth of common shares. Just after market close on Monday, Dyne announced that it has launched an underwritten public ...

Dyne Therapeutics is advancing z-rostudirsen toward approval for DMD after data showed increased dystrophin and early ...

Dyne Therapeutics leverages its FORCE platform to target genetically driven muscle diseases with two lead clinical programs approaching pivotal milestones. DYNE-101 shows strong safety and functional ...